Overexpression of CAV3 facilitates bone formation via the Wnt signaling pathway in osteoporotic rats
Osteoporosis is a condition characterized by decreased bone density and bone strength, commonly observed among older individuals. Caveolin-3 (CAV3) is a principal structural protein of the caveolae membrane domains, which has been reported to participate in cell signaling as well as the maintenance of cell structure. The aim of the current study was to investigate the effects involved with the silencing of CAV3 on bone formation among osteoporotic rat models via the Wnt signaling pathway.
Osteoporosis was initially induced by means of ovariotomy among rat models in order to determine the expression of CAV3. Then, to confirm the specific function and mechanism of CAV3 from an osteoporosis perspective, the CAV3 expression vector was constructed and transfected into the osteoblasts of the osteoporotic rats. Afterward, the mRNA and protein expressions of CAV3, β-catenin, low-density lipoprotein receptor-related protein 5 (LRP5), T-cell factor (TCF), and Wnt3a in addition to cell proliferation and apoptosis were detected accordingly.
Positive expression of CAV3 exhibited diminished levels in the bone tissues of osteoporotic rats. The osteoblasts of the osteoporotic rats treated with overexpressed CAV3 displayed elevated mRNA and protein expression levels of β-catenin, LRP5, TCF, and Wnt3a. Increased cell proliferation and decreased cell apoptosis were also observed, while the osteoblasts of the osteoporotic rats treated with si-CAV3 exhibited an opposite result.
Overexpressed CAV3 promotes bone formation and suppresses the osteoporosis progression via the activation of the Wnt signaling in rat models, suggesting CAV3 as a potential target biomarker in the treatment of osteoporosis.
KeywordsOsteoporosis CAV3 Gene silencing Wnt signaling pathway Bone formation
We would like to acknowledge the helpful comments on this paper received from our reviewers.
This study was supported by Fuzhou Science and Technology Bureau (No. 2013-S-123-4) and Natural Science Foundation of Fujian Province (No. 2016J01598).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All animal operations in this study were performed was in line with the local principles of management and use of experimental animals.
- 5.K. Lippuner, The future of osteoporosis treatment - a research update. Swiss Med. Wkly 142, w13624 (2012)Google Scholar
- 13.G. Yuan, I. Regel, F. Lian, T. Friedrich, I. Hitkova, R.D. Hofheinz, P. Strobel, R. Langer, G. Keller, C. Rocken, W. Zimmermann, R.M. Schmid, M.P. Ebert, E. Burgermeister, WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene 32(3), 375–387 (2013)CrossRefGoogle Scholar
- 15.K. Jensen, R. Krusenstjerna-Hafstrom, J. Lohse, K.H. Petersen, H. Derand, A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. Mod. Pathol. 30(2), 180–193 (2017)CrossRefGoogle Scholar
- 18.Y. Miyauchi, Y. Sato, T. Kobayashi, S. Yoshida, T. Mori, H. Kanagawa, E. Katsuyama, A. Fujie, W. Hao, K. Miyamoto, T. Tando, H. Morioka, M. Matsumoto, P. Chambon, R.S. Johnson, S. Kato, Y. Toyama, T. Miyamoto, HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc. Natl. Acad. Sci. USA 110(41), 16568–16573 (2013)CrossRefGoogle Scholar
- 21.S. Zenger, K. Hollberg, J. Ljusberg, M. Norgard, B. Ek-Rylander, R. Kiviranta, G. Andersson, Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 41(5), 820–832 (2007)CrossRefGoogle Scholar
- 24.J. Korvala, H. Juppner, O. Makitie, E. Sochett, D. Schnabel, S. Mora, C.F. Bartels, M.L. Warman, D. Deraska, W.G. Cole, H. Hartikka, L. Ala-Kokko, M. Mannikko, Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. Bmc. Med. Genet. 13, 26 (2012)CrossRefGoogle Scholar
- 28.J. Su, A. Zhang, Z. Shi, F. Ma, P. Pu, T. Wang, J. Zhang, C. Kang, Q. Zhang, MicroRNA-200a suppresses the Wnt/beta-catenin signaling pathway by interacting with beta-catenin. Int. J. Oncol. 40(4), 1162–1170 (2012)Google Scholar
- 32.S. Bousserouel, M. Raymondjean, A. Brouillet, G. Bereziat, M. Andreani, Modulation of cyclin D1 and early growth response factor-1 gene expression in interleukin-1beta-treated rat smooth muscle cells by n-6 and n-3 polyunsaturated fatty acids. Eur. J. Biochem. 271(22), 4462–4473 (2004)CrossRefGoogle Scholar
- 33.F. Fang, W.Y. Zhao, R.K. Li, X.M. Yang, J. Li, J.P. Ao, S.H. Jiang, F.Z. Kong, L. Tu, C. Zhuang, W.X. Qin, P. He, W.M. Zhang, H. Cao, Z.G. Zhang, Silencing of WISP3 suppresses gastric cancer cell proliferation and metastasis and inhibits Wnt/beta-catenin signaling. Int. J. Clin. Exp. Pathol. 7(10), 6447–6461 (2014)Google Scholar